Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Find a Tender Service (FTS) |
| Notice Type: | Award notice |
| Buyer: | NHS ENGLAND |
| Main Category: | Goods |
| Procurement Method: | Open procedure |
| Tender Status: | Closed |
| Estimated Value (ex. VAT): | Not specified |
| Release Date: | 1 August 2025 |
| Application Deadline: | — |
| Contract Start Date: | — |
| Contract End Date: |
All 4 notices for this procurement, oldest first.
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025
View Original Notice
Access the full notice on the official portal
🤝 Need a consortium or subcontracting partner?
SMEs & Primes team up to win opportunities like this. Find partners on the board.
Awarded to (15 suppliers)
NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025 Offer reference number: CM/PHS/25/5728 Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum of 24 months. Potential periods of call-offs under the framework agreement: CM/PHS/25/5728/01 - National Framework for Medical Retinal Vascular Treatments: 7NAT (National) 01/12/2025 to 31/05/2027 (18 months) CM/PHS/25/5728/02 - Regional Framework for Medical Retinal Vascular Treatments aflibercept 2mg: NOFE: (North of England) 01/12/2025 to 31/05/2027 (18 months) SOFE: (South of England) 01/12/2025 to 31/05/2027 (18 months) MAE: (Midlands and East) 01/12/2025 to 31/05/2027 (18 months) LNW: (London) 01/12/2025 to 31/05/2027 (18 months) Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England Provision of Licensed Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye
Published contracts in the last 12 months
35
total contracts
£415.4m
total value
£31,953,453
average contract size
Typical categories
NHS England Digital Pathways Solution Registry in the Primary Care Setting
NHS ENGLAND · WAC-635496
Supplier Ambient Voice Technology (AVT) Self Certified Registry for the use of AI-Enabled Ambient Scribing Products in Health and Care Settings
NHS ENGLAND · WAC-631985
NHS England Information Request to inform the creation of a Supplier Registry for Digital Pathway Solutions in the Primary Care Setting
NHS ENGLAND · WAC-615363
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| — |
| Contract Duration: | NaN years |
| Procurement ID (OCID): | ocds-h6vhtk-055064 |
| Notice Reference: | 045153-2025 |
| Award value: | £688,834,174 |
| Award decision date: | — |
| Award status: | Pending |